Biotech Values

[DewDiligence]

Biotech buyouts that have included contingent-value rights:

• CELG’s purchase of Abraxis Bioscience (2010)
• LGND’s purchase of Metabasis (2010)
• LGND’s purchase of Neurogen (2009)
• ENDP’s of Indevus Pharmaceuticals (2009)
• MDCO’s purchase of Targanta (2009)
• Fresenius’ purchase of APP Pharma (2008)
• LGND’s purchase of Pharmacopeia (2008)
• VPHM’s purchase of Lev (2008)
• OSIP’s purchase of Cell Pathways (2003)

Source: http://blogs.wsj.com/health/2011/02/14/the-stats-on-contingent-value-rights-in-pharma-deals